Efficacy and safety of dupilumab in patients with prurigo nodularis.
作者信息
Li Xu, Li Jiaojiao, Li Dan, Guo Jingxue, Yang Xueying, Fan Change, Cai Huijiao, An Caiyan, Li Yanfei, Zhang Junjing
机构信息
Department of Allergy, The First Hospital of Hohhot, Hohhot, 010030, China.
Department of Dermatology, The First Hospital of Hohhot, Hohhot, 010030, China.
出版信息
Arch Dermatol Res. 2024 Oct 14;316(10):676. doi: 10.1007/s00403-024-03387-1.
PMID:39400706
Abstract
摘要
相似文献
1
Efficacy and safety of dupilumab in patients with prurigo nodularis.度普利尤单抗治疗结节性痒疹患者的疗效和安全性。
Arch Dermatol Res. 2024 Oct 14;316(10):676. doi: 10.1007/s00403-024-03387-1.
2
A critical review of dupilumab for adult patients with prurigo nodularis.度普利尤单抗治疗成年结节性痒疹患者的批判性综述。
Expert Rev Clin Immunol. 2024 Mar;20(3):249-254. doi: 10.1080/1744666X.2023.2268291. Epub 2023 Oct 12.
3
Dupilumab for prurigo nodularis: Case series and review of the literature.度普利尤单抗治疗结节性痒疹：病例系列及文献综述
Dermatol Ther. 2020 Mar;33(2):e13222. doi: 10.1111/dth.13222. Epub 2020 Jan 16.
4
Effectiveness and safety of dupilumab for the treatment of prurigo nodularis in a French multicenter adult cohort of 16 patients.度普利尤单抗治疗16例法国多中心成年结节性痒疹患者的有效性和安全性。
J Eur Acad Dermatol Venereol. 2020 Feb;34(2):e74-e76. doi: 10.1111/jdv.15957. Epub 2019 Oct 17.
5
Dupilumab for the treatment of prurigo nodularis: A systematic review.度普利尤单抗治疗结节性痒疹的系统评价。
Front Immunol. 2023 Jan 20;14:1092685. doi: 10.3389/fimmu.2023.1092685. eCollection 2023.
6
Safety and Effectiveness of Dupilumab in Prurigo Nodularis.度普利尤单抗治疗结节性痒疹的安全性和有效性。
J Investig Allergol Clin Immunol. 2021 Apr 20;31(2):162-163. doi: 10.18176/jiaci.0550. Epub 2020 Jun 23.
7
Baseline eosinophil level may be a predictive indicator for the effectiveness of dupilumab in patients with prurigo nodularis: A single-center, real-world prospective study.基线嗜酸性粒细胞水平可能是结节性痒疹患者使用度普利尤单抗疗效的预测指标：一项单中心、真实世界的前瞻性研究。
J Am Acad Dermatol. 2024 May;90(5):1076-1078. doi: 10.1016/j.jaad.2024.01.036. Epub 2024 Jan 29.
8
Dupilumab in Treatment of Chronic Prurigo: A Case Series and Literature Review.度普利尤单抗治疗慢性痒疹：病例系列及文献综述
Acta Derm Venereol. 2019 Sep 1;99(10):905-906. doi: 10.2340/00015555-3243.
9
Long-term therapeutic response to dupilumab in patients affected by prurigo nodularis: A real-world retrospective study.度普利尤单抗治疗结节性痒疹患者的长期疗效：一项真实世界回顾性研究。
J Eur Acad Dermatol Venereol. 2024 Oct;38(10):e892-e895. doi: 10.1111/jdv.19980. Epub 2024 Mar 27.
10
Dupilumab for pediatric prurigo nodularis: A case report.度普利尤单抗治疗儿童结节性痒疹：一例报告
Pediatr Dermatol. 2021 Jan;38(1):334-335. doi: 10.1111/pde.14464. Epub 2020 Nov 28.
本文引用的文献
1
Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials.度普利尤单抗治疗结节性痒疹患者的两项随机、双盲、安慰剂对照 3 期临床试验。
Nat Med. 2023 May;29(5):1180-1190. doi: 10.1038/s41591-023-02320-9. Epub 2023 May 4.
2
Prurigo nodularis: Pathogenesis and management.结节性痒疹：发病机制与治疗。
J Am Acad Dermatol. 2020 Dec;83(6):1567-1575. doi: 10.1016/j.jaad.2020.04.182. Epub 2020 May 24.
3
Prurigo nodularis: Epidemiology and clinical features.结节性痒疹：流行病学和临床特征。
J Am Acad Dermatol. 2020 Dec;83(6):1559-1565. doi: 10.1016/j.jaad.2020.04.183. Epub 2020 May 23.
Zotero 插件